Kairos Pharma: Potential To Remove Resistance With Established Drugs

Company Overview - Kairos Pharma (NYSE: KAPA) is focused on developing several oncology drugs aimed at overcoming resistance seen with existing therapies [2] Pipeline Development - The primary clinical drug in Kairos Pharma's pipeline is ENV105, which acts as a CD105 inhibitor [2]